Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Slides:

Advertisements

Similar presentations

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer Victor E. Chen, BS, Erin.

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Management of independent motion between multiple targets in lung cancer radiation therapy Feng Liu, PhD, An Tai, PhD, Ergun Ahunbay, PhD, Elizabeth.

Efficacy and toxicity of rectal cancer reirradiation using IMRT for patients who have received prior pelvic radiation therapy Fady F. Youssef, MS, Parag.

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Jennifer C. Ho, MD, Quynh-Nhu Nguyen, MD, Heng Li, PhD, Pamela K

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Dawn Owen, MD, PhD, Nadia N. Laack, MD, MSc, Charles S

Brenda G. Clark, PhD, Robert J

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis Annemarie T. Fernandes, BA, Eric.

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer

Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree Justin M. Haseltine, BSE,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Dosimetric comparison of 3-dimensional conformal radiation therapy and intensity modulated radiation therapy and impact of setup errors in lower limb.

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection Shalini Garg, MD,

Intramedullary Reactive Fibrosis as Mimic of Prostate Cancer Bone Metastasis on 11C- Choline Positron Emission and Computed Tomography Tyler Trump, BS,

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Practical Radiation Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer Charles M. Rudin, MD, PhD,

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic.

ITV-Based Robust Optimization for VMAT Planning of Stereotactic Body Radiation Therapy of Lung Cancer Xiaoying Liang, PhD, Dandan Zheng, PhD, Maria Mamalui-Hunter,

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center

Effect of Daily and Every Other Day Stereotactic Body Radiation Therapy Schedules on Treatment-Related Fatigue in Patients With Hepatocellular Carcinoma

Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer Nami.

An Editorial Note: The Long Arm of Practical Radiation Oncology

Perioperative outcomes and amputation-free survival after lower extremity bypass surgery in California hospitals, , with follow-up through 2004

Burnout and Resiliency in Canadian Oncology Residents: A Nationwide Resident and Program Director Survey Hannah Dahn, MD, Angela McGibbon, MD, David.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III.

Expression and Mutational Status of c-kit in Thymic Epithelial Tumors

Khaled Adil, MD, Marija Popovic, PhD, Fabio L. Cury, MD, Sergio L

Stereotactic Body Radiation Therapy for Primary Lung Cancers >3 Centimeters John J. Cuaron, MD, Ellen D. Yorke, PhD, Amanda Foster, BA, Meier Hsu, MS,

Long-Term Results of Radiofrequency Ablation Treatment of Stage I Non-small Cell Lung Cancer: A Prospective Intention-to-Treat Study Marcello Carlo Ambrogi,

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

A Phase II Study of Concurrent Chemoradiation with Weekly Docetaxel, Carboplatin, and Radiation Therapy Followed by Consolidation Chemotherapy with Docetaxel.

Stereotactic Body Radiation Therapy for the Treatment of Primary Cardiac Angiosarcoma Causing Hemodynamic Instability Prashant Gabani, MD, Benjamin W.

Pulmonary Resection for Metastases from Colorectal Cancer

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas Kripa Guram, BS, Mark Smith,

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

International Thymic Malignancies Interest Group: A Way Forward

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study Hans Rostad, MD, PhD, Trond-Eirik Strand, MD, Anne Naalsund, MD, Jarle Norstein,

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Debby P. M. van den Bogaert, MD, Ellen M

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Presentation transcript:

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi, PhD, Sijin Wen, PhD, Malcolm D. Mattes, MD Practical Radiation Oncology Volume 9, Issue 1, Pages e90-e97 (January 2019) DOI: 10.1016/j.prro.2018.09.003 Copyright © 2018 American Society for Radiation Oncology Terms and Conditions

Figure 1 Kaplan-Meier plots showing (A) overall survival for primary (solid) and metastatic (dashed) tumors, (B) local control for both primary and metastatic tumors, (C) PFS for patients with metastatic tumors, and (D) DFS for primary tumors. Abbreviations: PFS = progression-free survival; DFS = disease-free survival. Practical Radiation Oncology 2019 9, e90-e97DOI: (10.1016/j.prro.2018.09.003) Copyright © 2018 American Society for Radiation Oncology Terms and Conditions

Figure 2 Kaplan-Meier plots showing local control between small (<5 cm; solid) and large (≥5 cm; dashed) tumors. Practical Radiation Oncology 2019 9, e90-e97DOI: (10.1016/j.prro.2018.09.003) Copyright © 2018 American Society for Radiation Oncology Terms and Conditions